ENLV
Price
$1.06
Change
-$0.01 (-0.93%)
Updated
Sep 5 closing price
Capitalization
25.29M
86 days until earnings call
PBIGF
Price
$0.17
Change
-$0.02 (-10.53%)
Updated
Sep 4 closing price
Capitalization
73.93M
Interact to see
Advertisement

ENLV vs PBIGF

Header iconENLV vs PBIGF Comparison
Open Charts ENLV vs PBIGFBanner chart's image
Enlivex Therapeutics
Price$1.06
Change-$0.01 (-0.93%)
Volume$185.74K
Capitalization25.29M
Paradigm Biopharmaceuticals
Price$0.17
Change-$0.02 (-10.53%)
Volume$9.6K
Capitalization73.93M
ENLV vs PBIGF Comparison Chart in %
Loading...
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENLV vs. PBIGF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a Hold and PBIGF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ENLV: $1.06 vs. PBIGF: $0.17)
Brand notoriety: ENLV and PBIGF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENLV: 26% vs. PBIGF: 97%
Market capitalization -- ENLV: $25.29M vs. PBIGF: $73.93M
ENLV [@Biotechnology] is valued at $25.29M. PBIGF’s [@Biotechnology] market capitalization is $73.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENLV’s FA Score shows that 1 FA rating(s) are green whilePBIGF’s FA Score has 0 green FA rating(s).

  • ENLV’s FA Score: 1 green, 4 red.
  • PBIGF’s FA Score: 0 green, 5 red.
According to our system of comparison, ENLV is a better buy in the long-term than PBIGF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENLV’s TA Score shows that 5 TA indicator(s) are bullish while PBIGF’s TA Score has 3 bullish TA indicator(s).

  • ENLV’s TA Score: 5 bullish, 5 bearish.
  • PBIGF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ENLV is a better buy in the short-term than PBIGF.

Price Growth

ENLV (@Biotechnology) experienced а +0.95% price change this week, while PBIGF (@Biotechnology) price change was -8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

ENLV is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBIGF($73.9M) has a higher market cap than ENLV($25.3M). ENLV YTD gains are higher at: -9.402 vs. PBIGF (-37.934). ENLV has higher annual earnings (EBITDA): -14.04M vs. PBIGF (-15.46M).
ENLVPBIGFENLV / PBIGF
Capitalization25.3M73.9M34%
EBITDA-14.04M-15.46M91%
Gain YTD-9.402-37.93425%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash20.6MN/A-
Total Debt503KN/A-
FUNDAMENTALS RATINGS
ENLV vs PBIGF: Fundamental Ratings
ENLV
PBIGF
OUTLOOK RATING
1..100
394
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6492
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7519

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENLV's Valuation (18) in the Medical Specialties industry is significantly better than the same rating for PBIGF (86) in the null industry. This means that ENLV’s stock grew significantly faster than PBIGF’s over the last 12 months.

ENLV's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PBIGF (100) in the null industry. This means that ENLV’s stock grew similarly to PBIGF’s over the last 12 months.

PBIGF's SMR Rating (97) in the null industry is in the same range as ENLV (98) in the Medical Specialties industry. This means that PBIGF’s stock grew similarly to ENLV’s over the last 12 months.

ENLV's Price Growth Rating (64) in the Medical Specialties industry is in the same range as PBIGF (92) in the null industry. This means that ENLV’s stock grew similarly to PBIGF’s over the last 12 months.

ENLV's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as PBIGF (100) in the null industry. This means that ENLV’s stock grew similarly to PBIGF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENLVPBIGF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
39%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
35%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
50%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
47%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
38%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
46%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 19 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
44%
Aroon
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DHC4.120.23
+5.91%
Diversified Healthcare Trust
SNBR9.67-0.06
-0.62%
Sleep Number Corp
SAIC104.93-1.29
-1.21%
Science Applications International Corp
TRV275.22-4.21
-1.51%
Travelers Companies (The)
CKX11.81-0.23
-1.91%
CKX Lands

PBIGF and

Correlation & Price change

A.I.dvisor tells us that PBIGF and PSTV have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PBIGF and PSTV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBIGF
1D Price
Change %
PBIGF100%
N/A
PSTV - PBIGF
27%
Poorly correlated
+9.27%
ENLV - PBIGF
26%
Poorly correlated
-0.93%
OXBDF - PBIGF
7%
Poorly correlated
N/A
PTCHF - PBIGF
6%
Poorly correlated
N/A
NTRB - PBIGF
4%
Poorly correlated
+2.41%
More